Schizophrenia Bulletin – February 2018

The February edition of Schizophrenia Bulletin has been published.  This issue includes articles on journaling as therapy, auditory verbal hallucinations in schizophrenia from a levels of explanation perspective, and social disconnection in schizophrenia and the general community.

Click here to view the table of contents and access full text articles.  You will need to login with your LCFT OpenAthens account.

Advertisements

Schizophrenia Bulletin – January 2018

The January edition of Schizophrenia Bulletin has been published.  This issue includes articles on reducing voices by direct dialogue and the potential of cannabidiol treatment for cannabis users with recent-onset psychosis.

Click here to view the table of contents.

Click here to request an article from the Library.

Zuclopenthixol dihydrochloride for schizophrenia

Cochrane Database of Systematic Reviews, November 2017

This Cochrane Review finds evidence available suggest that zuclopenthixol dihydrochloride is not any worse than other antipsychotics in treating the symptoms of schizophrenia, however more trials providing good-quality data are needed before firm conclusions can be made.

Click here to view the full text.

 

Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II)

BMJ 2017;356:i6681 – January 2017

This randomised, superiority, parallel group trial aims to compare the effects of five years of specialised early intervention (SEI) treatment for first episode schizophrenia spectrum disorder with the standard two years of SEI plus three years of treatment as usual.

Click here to access the full text paper.

 

Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia

Cochrane Database of Systematic Reviews, October 2016

This review protocol was co-written by Graeme Reid, Consultant Clinical Psychologist at Lancashire Care NHS Foundation Trust.

The objectives are to examine the effects of occupational therapy delivered by occupational therapists compared to occupational therapy delivered by any other person for people with schizophrenia. Our secondary objectives are to determine whether the response differs by specific type (e.g. hospital versus non-hosptial setting), intensity (e.g. more therapist contact time or more frequent task repetition), or duration of occupational therapy.

Click here to access this protocol.

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial

National Institute of Health Research, April 2016

Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are currently no approved pharmacological treatments. While the available evidence suggests that a combination of antipsychotic and antidepressant medication may be effective in treating negative symptoms, it is too limited to allow any firm conclusions.

This trial aims to establish the clinical effectiveness and cost-effectiveness of augmentation of antipsychotic medication with the antidepressant citalopram for the management of negative symptoms in schizophrenia.

Click here to access the full text paper.